Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Factual Report
|
$115.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
CryoLife Inc Receives Regulatory Approval for BioFoam in Europe
CryoLife Inc announced that it has received regulatory approval in Europe to market its BioFoam Surgical Matrix as an adjunct to hemostasis in cardiovascular surgery when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BioFoam has previously been approved in Europe as an adjunct to hemostasis in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.
Latest Key Developments in Medical
- MIT Capital Inc Proposes To Acquire Meade Instruments Corp For $3.65 Per Share In Cash
- FDA Grants Prostate IDE Approval For Angiodynamics Inc's NanoKnife System
- Urban Ag Corp Announces It Has Entered Into The Final Stages Of Negotiations To Acquire Contractor Currently Generating $4,500,000 In Revenues
- HeartWare International Inc Receives Conditional Approval From FDA To Enroll Supplemental Patient Cohort In Destination Therapy Trial
- Share this
- Link this
- Digg this
Follow Reuters